500124:BOM
Dr Reddy's Laboratories Ltd
₹1,232.55
arrow_upward
+0.06%(+0.70) 1D
Okt 19, 11:57:03 AM GMT+5:30 · INR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa 500124...
Buksan
₹1,233.00
Mataas
₹1,243.00
Mababa
₹1,228.20
Mkt. cap
1.03T
Avg. na dami
90.88K
Dami
11.59K
Dividend
0.65%
Bawat tatlong buwang dividend
₹2.00
Petsa ng ex-dividend
Hul 10, 2026
P/E ratio
31.87
Mataas nang 52-wk
₹1,414.40
Mababa nang 52-wk
₹1,080.05
EPS
₹38.67
Mga natitirang share
166.06M
Bilang ng mga empleyado
28K
Buksan
₹1,233.00
Mataas
₹1,243.00
Mababa
₹1,228.20
Mkt. cap
1.03T
Avg. na dami
90.88K
Dami
11.59K
Dividend
0.65%
Bawat tatlong buwang dividend
₹2.00
Petsa ng ex-dividend
Hul 10, 2026
P/E ratio
31.87
Mataas nang 52-wk
₹1,414.40
Mababa nang 52-wk
₹1,080.05
EPS
₹38.67
Mga natitirang share
166.06M
Bilang ng mga empleyado
28K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketWatch
·
16 oras ang nakalipas
These surprising stocks could be some of the biggest drivers of S&P 500 earnings growth
Bloomberg.com
·
8 oras ang nakalipas
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
FXStreet
·
3 araw ang nakalipas
Dow Jones futures gains ahead of US PPI, Retail Sales data
Barron's
·
1 buwan ang nakalipas
Bloom Energy, Illumina, and Everpure Are Joining the S&P 500. These 3 Stocks Are Leaving.
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Tungkol sa Dr Reddy's Laboratories Ltd
CEOErez Israeli
Mga Empleyado27.5K
Itinatag1984
HeadquartersHyderabad, Andhra Pradesh, India
Sektor-
Websitedrreddys.com